By Fineline Cube 
CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a strategic partnership with China-based Contract Research Organization (CRO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759). The collaboration aims to validate CN Bio’s PhysioMimix technology and integrate OOC technologies into Pharmaron’s R&D platform.
Partnership Objectives
Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix technology across existing applications, including disease modeling, toxicity testing, and ADME studies. This validation will enhance the reliability and applicability of OOC systems in drug discovery and development.
Global Expansion and Innovation
The partnership will also focus on developing new applications for OOC technologies to address unmet needs in drug discovery. As part of this collaboration, CN Bio will install PhysioMimix instruments at Pharmaron’s facilities worldwide, enabling broader access to advanced OOC solutions.-Fineline Info & Tech